Observational Study of Patients Suffering From Endometriosis and Adenomyosis

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT04862000
Collaborator
(none)
880
1
140.1
6.3

Study Details

Study Description

Brief Summary

Endometriosis and adenomyosis are chronic difficult diseases affecting a significant proportion of reproductive age women. it is hoped that the investigators can collect the health profile of these participants using structured questionnaires on their quality of life, reproductive health, collect the sonographic characteristics, identify the risks factors of participants suffering from severe disease, and to propose the best treatment modality for different patient groups, both with and without fertility wish.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Endometriosis and adenomyosis are chronic difficult diseases affecting a significant proportion of reproductive age women. Not only the disease can lead to chronic pelvic pain, dyspareunia and dysmenorrhea, it is also associated with impaired reproductive health, infertility and tubal-peritoneal disease. Adenomyosis can also result in anaemia due to the increased uterine volume and menstrual blood loss. Different treatment options are available for this group of participants, ranging from simple medical treatment to control symptoms, such as analgesics for pain control, transexemic acid to reduce menstrual blood loss, to hormonal treatment and the more radical surgical treatment.

    As a tertiary gynaecology referral centre, the investigators encounter a large volume of patients suffering from endometriosis and adenomyosis of different disease severity. Through this prospective observational study, it is hoped that the investigators can collect the health profile of participants using structured questionnaires on their quality of life, reproductive health, collect the sonographic characteristics, identify the risks factors of patients suffering from severe disease, and to propose the best treatment modality for different participant groups, both with and without fertility wish.

    Patients attending the pelvic mass clinic/ endometriosis clinic with the histologically confirmed or sonographic evidence of endometriosis/ adenomyosis will be invited to participate in the prospective study. Their demographic data will be collected. Symptomatology and health profile will be collected via questionnaires (e.g.EHP-30, SF 36, FSFI) to evaluate the physical, psychological, sexual and social aspects of patients affecting by the disease. Menstrual chart with be recorded. Physical examination including abdominal and pelvic examination will be performed. Pelvic sonography will be offered and recorded systematically. Different medical/ surgical treatments will be offered based on patient's clinical condition in an evidence-based approach and clinical guidance. Their treatment outcome will be assessed during the follow-up. Surgical findings will be recorded and disease severity graded by use of AFS scores. Pathological findings will be evaluated.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    880 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Prospective Long Term Observational Study of Health Profile, Clinical Characteristics and Outcome of Patients Suffering From Endometriosis and Adenomyosis
    Actual Study Start Date :
    Apr 30, 2021
    Anticipated Primary Completion Date :
    Dec 31, 2031
    Anticipated Study Completion Date :
    Dec 31, 2032

    Arms and Interventions

    Arm Intervention/Treatment
    Endometriosis or adenomyosis

    participants suffering pelvic endometriosis, endometrioma, deep infiltrating endometriosis or adenomyosis

    Outcome Measures

    Primary Outcome Measures

    1. Endometriosis Health Profile (EHP-30) questionnaire score [from enrollment to end of treatment at five years.]

      The Endometriosis Health Profile-30 (EHP-30) is a disease-specific questionnaire to measure the health-related quality of life in patients with endometriosis. EHP-30 score is ranging from 0 (best health status) to 100 (worst health status). EHP-30 questionnaire score before and after medical and surgical treatment will be evaluated.

    2. Visual Analog Scale (VAS) pain score [from enrollment to end of treatment at five years.]

      The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by participant making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain." Mean change in pain score on VAS before and after medical and surgical treatment will be evaluated.

    Secondary Outcome Measures

    1. side effects profile of medical treatment [from the first follow up at six months to end of treatment at five years.]

      side effects profile of medical treatment for endometriosis and adenomyosis. The bone mineral density measurement (DEXA) will be arranged if participants has prolonged usage of progestogens over 2 years. Menstrual pattern will be recorded using menstrual calendar.

    2. ultrasound findings correlation with surgical findings [from enrollment to three months post-surgery]

      ultrasound findings correlation with surgical findings using AFS scores and Endometriosis fertility index EFI scores

    3. symptoms recurrence [from enrollment to end of treatment at five years.]

      symptoms recurrence including pelvic pain, menstrual problems and endometrioma recurrence after medical or surgical treatments

    4. reproductive outcome [from enrollment to end of treatment at five years.]

      evaluate the reproductive outcome in those participants with fertility wish. Spontaneous pregnancy rates and requirement for assisted reproductive technology after surgery will be studied, with reference to the intraoperative AFS scores.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:
    • with endometriosis or adenomyosis confirmed by ultrasound or MRI
    Exclusion Criteria:
    • refuse to participate in the study, less than 18 years old, menopausal, illiterate or mentally incapable

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Chinese University of Hong Kong Hong Kong Hong Kong

    Sponsors and Collaborators

    • Chinese University of Hong Kong

    Investigators

    • Principal Investigator: Wen Ying Linda FUNG, Chinese University of Hong Kong

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fung Wen Ying Linda, Associate Consultant, Chinese University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT04862000
    Other Study ID Numbers:
    • CRE 2020.688
    First Posted:
    Apr 27, 2021
    Last Update Posted:
    Jul 6, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Fung Wen Ying Linda, Associate Consultant, Chinese University of Hong Kong
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 6, 2022